X4 Pharmaceuticals, Inc.

NASDAQ:XFOR

Biotechnology

Healthcare
$2.96 +1.49%

+$0.06 today

Market cap
$302.26M
Beta
0.37
P/E (TTM)
-5.2
EPS (TTM)
-$0.79
52W Low $1.35High $4.83

Volume 1.12M

Average 0.40M

Income Statement

Follow revenue through to earnings.

Revenue

$35.11M

FY 2025 · Annual

+1273.2% YoY

Operating Income

-$86.88M

FY 2025 · Annual

Net Income

-$79.20M

FY 2025 · Annual

Income Statement

USD
Metric
FY 2021
Dec 2021
FY 2022
Dec 2022
FY 2023
Dec 2023
FY 2024
Dec 2024
FY 2025
Dec 2025
Revenue0002.56M35.11M
Cost of Revenue1.89M00797K6.26M
Gross Profit(1.89M)001.76M28.86M
Gross Margin———68.8%82.2%
Research & Development48.76M61.06M72.02M81.64M72.22M
Selling, General & Admin24.7M27.02M35.51M61.52M43.52M
Operating Expenses73.46M87.57M107.52M38.16M115.74M
Depreciation & Amortization1.89M513K419K796K1.28M
EBITDA(83.15M)(89.33M)(94.89M)(27.58M)(69.01M)
EBITDA Margin———-1078.5%-196.5%
Operating Income(75.35M)(87.57M)(107.52M)(36.4M)(86.88M)
Operating Margin———-1423.6%-247.4%
Interest Income10K219K4.58M5.77M4.58M
Interest Expense3.64M3.99M5.78M8.77M8.88M
Other Income / Expenses(13.33M)(6.27M)6.43M(739K)7.73M
Income Before Tax(88.68M)(93.84M)(101.09M)(37.14M)(79.16M)
Pre-Tax Margin———-1452.5%-225.4%
Income Tax Expense17K28K78K310K41K
Net Income(88.7M)(93.87M)(101.17M)(37.45M)(79.2M)
Net Margin———-1464.6%-225.6%
EPS (Basic)(119.58)(45.60)(17.07)(5.59)(1.87)
EPS (Diluted)(119.58)(45.60)(17.07)(5.59)(1.87)
Weighted Avg Shares858.3K2.12M5.93M6.7M42.29M
Weighted Avg Shares (Diluted)858.3K2.12M5.93M6.7M42.29M

XFOR Earnings Waterfall · TTM

NASDAQ:XFOR · Revenue to Net Income

Key Ratios

EPS$-4.54
Gross Margin79.2%
Net Margin-1168.3%
P/E Ratio-3.1
P/S Ratio113.9

Analysis

$9.0M of revenue converted into -$99.7M of net income for the selected period. Gross margin is 79.2% and net margin is -1168.3%, showing how much revenue survives after costs and taxes. EPS is $-4.54, tying the income statement back to per-share earnings.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
SC 13G/ASC 13G/A filingNov 13, 2026
10-QQuarterly reportNov 4, 2026
8-KCurrent reportOct 29, 2026
4Statement of changes in beneficial ownershipOct 19, 2026
8-KCurrent reportOct 8, 2026

How much revenue does XFOR generate?

X4 Pharmaceuticals, Inc. (XFOR) reported $35.11M of revenue in fiscal 2025.

Is XFOR profitable?

X4 Pharmaceuticals, Inc. (XFOR) reported -$79.20M of net income, with a net margin of -225.6%.